首页> 美国卫生研究院文献>Frontiers in Endocrinology >Review on the Utility of Trabecular Bone Score a Surrogate of Bone Micro-architecture in the Chronic Kidney Disease Spectrum and in Kidney Transplant Recipients
【2h】

Review on the Utility of Trabecular Bone Score a Surrogate of Bone Micro-architecture in the Chronic Kidney Disease Spectrum and in Kidney Transplant Recipients

机译:骨小梁评分骨微结构的替代物慢性肾脏疾病谱和肾移植受者的效用的审查。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for >3 months, with implications for, among others, bone health. Advanced stages of CKD have an increased risk of fragility fractures. Trabecular bone score (TBS) is a relatively new gray-level textural parameter, which provides information on bone microarchitecture and has been shown to be a good predictor of fragility fractures independently of bone density and clinical risk factors. We aimed to review the scientific literature on TBS and its utility along the CKD spectrum and in kidney transplant recipients. In total, eight articles had investigated this topic: one article in patients with reduced kidney function, two in patients on hemodialysis, and five in kidney transplant recipients. In general, all the studies had shown an association between lower values of TBS and reduced kidney function; or lower TBS values among the hemodialysis or kidney transplant patients compared to healthy controls. Moreover, TBS was shown to be a good and independent predictor of fragility fractures in patients with CKD or who underwent kidney transplantation. TBS postulates itself as a valuable marker to be used in clinical practice as an assessor of bone microarchitecture and fracture risk predictor in these specific populations. However, evidence is to some extent limited and larger follow-up case-control studies would help to further investigate the TBS utility in the management of bone health damage and increased fracture risk in patients with CKD or kidney transplant.
机译:慢性肾脏病(CKD)定义为存在超过3个月的肾脏结构或功能异常,其中包括骨骼健康。 CKD晚期会增加脆性骨折的风险。骨小梁评分(TBS)是一个相对较新的灰度级纹理参数,可提供有关骨骼微结构的信息,并且已被证明是独立于骨密度和临床危险因素的脆性骨折的良好预测指标。我们旨在回顾有关TBS及其在CKD谱中以及在肾移植受者中的效用的科学文献。总共有八篇文章调查了该主题:一篇针对肾功能不全的患者,另一篇针对血液透析患者,五篇针对肾移植患者。总的来说,所有研究均表明较低的TBS值与肾功能降低之间存在关联。或血液透析或肾脏移植患者中的TBS值低于健康对照者。此外,在患有CKD或接受肾脏移植的患者中,TBS被证明是脆性骨折的良好且独立的预测指标。 TBS假定自己是有价值的标志物,可在临床实践中用作这些特定人群的骨微结构评估者和骨折风险预测者。然而,证据在一定程度上是有限的,并且更大范围的随访病例对照研究将有助于进一步研究TBS在CKD或肾脏移植患者中管理骨骼健康损害和增加骨折风险的效用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号